National and Kapodistrian University of Athens
Διερεύνηση προγνωστικών παραγόντων και καρκινικών δεικτών στον καρκίνο του παγκρέατος
Abstract
dc:descriptionThe majority of patients with pancreatic adenocarcinoma present with locally advanced or metastatic disease at the time of diagnosis with only 15-20% presenting with a resectable tumor. Furthermore, a large percentage does not respond well to treatment and this is evident from the poor overall 5-year survival rates, which rarely exceed 5% The aim of the present study was to identify prognostic factors that are significantly related to survival in patients with pancreatic adenocarcinoma in order to select and categorize patients into groups that might benefit from chemotherapy compared to best supportive care. In this retrospective study we analyzed the data from the history files of 215 patients from the oncology units of the participating hospitals. A series of 23 variables were analyzed statistically by regression analysis to identify factors that correlated with overall survival. The overall median survival time was 25 weeks (mean survival 29,0±17,6 weeks ,range 3 to 92 weeks). The 3 year survival was calculated at 21,9%±2,8%. Among the 23 potential prognostic variables investigated initially at univariate analysis , 18 variables were identified as factors significantly associated with survival time. In multivariate analysis, using the Cox regression model, 9 variables demonstrated a significant effect on survival and were noted as independent prognostic factors. These included: tumor localization to the tail of the pancreas, multiple metastases, weight loss, performance status, jaundice, increased CRP levels, increased CEA levels, chemotherapy and surgery. We conclude that the evaluation of the prognostic significance of basic clinical, biochemical and therapeutic parameters may be a useful tool in the selection and categorization of patients who may benefit from chemotherapy and generally in the determination of appropriate treatment strategies as well as a rationale to design future therapeutic trials of systemic chemotherapy for pancreatic cancer
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2008
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Panantoniou, Nikitas
- Παπαντωνίου, Νικήτας
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/24010